Siddiqi Najma, Harrison Jennifer K, Clegg Andrew, Teale Elizabeth A, Young John, Taylor James, Simpkins Samantha A
Department of Health Sciences, University of York, Heslington, York, North Yorkshire, UK, Y010 5DD.
Cochrane Database Syst Rev. 2016 Mar 11;3(3):CD005563. doi: 10.1002/14651858.CD005563.pub3.
Delirium is a common mental disorder, which is distressing and has serious adverse outcomes in hospitalised patients. Prevention of delirium is desirable from the perspective of patients and carers, and healthcare providers. It is currently unclear, however, whether interventions for preventing delirium are effective.
To assess the effectiveness of interventions for preventing delirium in hospitalised non-Intensive Care Unit (ICU) patients.
We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 December 2015 for all randomised studies on preventing delirium. We also searched MEDLINE (Ovid SP), EMBASE (Ovid SP), PsycINFO (Ovid SP), Central (The Cochrane Library), CINAHL (EBSCOhost), LILACS (BIREME), Web of Science core collection (ISI Web of Science), ClinicalTrials.gov and the WHO meta register of trials, ICTRP.
We included randomised controlled trials (RCTs) of single and multi- component non-pharmacological and pharmacological interventions for preventing delirium in hospitalised non-ICU patients.
Two review authors examined titles and abstracts of citations identified by the search for eligibility and extracted data independently, with any disagreements settled by consensus. The primary outcome was incidence of delirium; secondary outcomes included duration and severity of delirium, institutional care at discharge, quality of life and healthcare costs. We used risk ratios (RRs) as measures of treatment effect for dichotomous outcomes; and between group mean differences and standard deviations for continuous outcomes.
We included 39 trials that recruited 16,082 participants, assessing 22 different interventions or comparisons. Fourteen trials were placebo-controlled, 15 evaluated a delirium prevention intervention against usual care, and 10 compared two different interventions. Thirty-two studies were conducted in patients undergoing surgery, the majority in orthopaedic settings. Seven studies were conducted in general medical or geriatric medicine settings.We found multi-component interventions reduced the incidence of delirium compared to usual care (RR 0.69, 95% CI 0.59 to 0.81; seven studies; 1950 participants; moderate-quality evidence). Effect sizes were similar in medical (RR 0.63, 95% CI 0.43 to 0.92; four studies; 1365 participants) and surgical settings (RR 0.71, 95% CI 0.59 to 0.85; three studies; 585 participants). In the subgroup of patients with pre-existing dementia, the effect of multi-component interventions remains uncertain (RR 0.90, 95% CI 0.59 to 1.36; one study, 50 participants; low-quality evidence).There is no clear evidence that cholinesterase inhibitors are effective in preventing delirium compared to placebo (RR 0.68, 95% CI, 0.17 to 2.62; two studies, 113 participants; very low-quality evidence).Three trials provide no clear evidence of an effect of antipsychotic medications as a group on the incidence of delirium (RR 0.73, 95% CI, 0.33 to 1.59; 916 participants; very low-quality evidence). In a pre-planned subgroup analysis there was no evidence for effectiveness of a typical antipsychotic (haloperidol) (RR 1.05, 95% CI 0.69 to 1.60; two studies; 516 participants, low-quality evidence). However, delirium incidence was lower (RR 0.36, 95% CI 0.24 to 0.52; one study; 400 participants, moderate-quality evidence) for patients treated with an atypical antipsychotic (olanzapine) compared to placebo (moderate-quality evidence).There is no clear evidence that melatonin or melatonin agonists reduce delirium incidence compared to placebo (RR 0.41, 95% CI 0.09 to 1.89; three studies, 529 participants; low-quality evidence).There is moderate-quality evidence that Bispectral Index (BIS)-guided anaesthesia reduces the incidence of delirium compared to BIS-blinded anaesthesia or clinical judgement (RR 0.71, 95% CI 0.60 to 0.85; two studies; 2057 participants).It is not possible to generate robust evidence statements for a range of additional pharmacological and anaesthetic interventions due to small numbers of trials, of variable methodological quality.
AUTHORS' CONCLUSIONS: There is strong evidence supporting multi-component interventions to prevent delirium in hospitalised patients. There is no clear evidence that cholinesterase inhibitors, antipsychotic medication or melatonin reduce the incidence of delirium. Using the Bispectral Index to monitor and control depth of anaesthesia reduces the incidence of postoperative delirium. The role of drugs and other anaesthetic techniques to prevent delirium remains uncertain.
谵妄是一种常见的精神障碍,给住院患者带来痛苦并产生严重不良后果。从患者、护理人员及医疗服务提供者的角度来看,预防谵妄是很有必要的。然而,目前尚不清楚预防谵妄的干预措施是否有效。
评估预防非重症监护病房(ICU)住院患者谵妄的干预措施的有效性。
2015年12月4日,我们检索了ALOIS(Cochrane痴呆与认知改善小组的专业注册库),以查找所有关于预防谵妄的随机研究。我们还检索了MEDLINE(Ovid SP)、EMBASE(Ovid SP)、PsycINFO(Ovid SP)、CENTRAL(Cochrane图书馆)、CINAHL(EBSCOhost)、LILACS(BIREME)、科学引文索引核心合集(ISI Web of Science)、ClinicalTrials.gov以及世界卫生组织试验注册平台ICTRP。
我们纳入了针对非ICU住院患者预防谵妄的单组分和多组分非药物及药物干预的随机对照试验(RCT)。
两名综述作者检查检索到的文献标题和摘要以确定是否符合纳入标准,并独立提取数据,如有分歧通过协商解决。主要结局是谵妄的发生率;次要结局包括谵妄的持续时间和严重程度、出院时的机构护理情况、生活质量以及医疗费用。对于二分法结局,我们使用风险比(RR)作为治疗效果的衡量指标;对于连续结局,我们使用组间均值差异和标准差。
我们纳入了39项试验,共招募了16082名参与者,评估了22种不同的干预措施或对照。14项试验为安慰剂对照,15项评估了预防谵妄干预措施与常规护理的比较,10项比较了两种不同的干预措施。32项研究在接受手术的患者中进行,大多数在骨科环境中。7项研究在普通内科或老年医学环境中进行。我们发现,与常规护理相比,多组分干预措施降低了谵妄的发生率(RR = 0.69,95%CI 0.59至0.81;7项研究;1950名参与者;中等质量证据)。在医学(RR = 0.63,95%CI 0.43至0.92;4项研究;1365名参与者)和手术环境(RR = 0.71,95%CI 0.59至0.85;3项研究;585名参与者)中,效应大小相似。在已有痴呆的患者亚组中,多组分干预措施的效果仍不确定(RR = 0.90,95%CI 0.59至1.36;1项研究,50名参与者;低质量证据)。没有明确证据表明与安慰剂相比,胆碱酯酶抑制剂在预防谵妄方面有效(RR = 0.68,95%CI 0.17至2.62;2项研究,113名参与者;极低质量证据)。三项试验没有提供明确证据表明抗精神病药物作为一个整体对谵妄发生率有影响(RR = 0.73,95%CI 0.3至